Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Income towards Parent Company (2013 - 2026)

Scynexis' (SCYX) quarterly Income towards Parent Company came in at -$7.1 million in Q2 2026, down 2.98% on a YoY basis from -$7.3 million in Q2 2025, and up 56.78% quarter-over-quarter from -$16.4 million in Q1 2026.

Analysis

Scynexis (SCYX) Income towards Parent Company (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Income towards Parent Company for 14 consecutive years, with -$7.1 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income towards Parent Company fell 2.98% year-over-year to -$7.1 million; the trailing twelve-month figure through Jun 2026 stood at -$18.0 million (down 20.73% YoY), and the FY2025 full-year result was -$6.8 million, up 59.26% from the prior year.
  • Income towards Parent Company improved to -$7.1 million in Q2 2026 per SCYX's latest filing, from -$16.4 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $122.3 million in Q2 2023 and bottomed at -$33.9 million in Q1 2023.
  • Historically, Income towards Parent Company has averaged -$2.7 million across 5 years, with a median of -$6.4 million in 2022.
  • The sharpest annual moves came in 2022 and 2025: Income towards Parent Company slumped 4789.92% in 2022, then surged 8857.96% in 2025.
  • Over 5 years, Income towards Parent Company stood at -$6.0 million in 2022, then slumped by 463.33% to -$33.5 million in 2023, then surged by 100.47% to $157000.0 in 2024, then soared by 8857.96% to $14.1 million in 2025, then plunged by 150.41% to -$7.1 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$7.1 million, -$16.4 million, and $14.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Scynexis 58.41 Mn -56.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -7.09 Mn
Mar 31, 2026 -16.40 Mn
Dec 31, 2025 14.06 Mn
Sep 30, 2025 -8.59 Mn
Jun 30, 2025 -6.89 Mn
Mar 31, 2025 -5.39 Mn
Dec 31, 2024 157,000.00
Sep 30, 2024 -2.81 Mn
Jun 30, 2024 -14.46 Mn
Mar 31, 2024 411,000.00
Dec 31, 2023 -33.54 Mn
Sep 30, 2023 -1.76 Mn
Jun 30, 2023 122.26 Mn
Mar 31, 2023 -33.88 Mn
Dec 31, 2022 -5.95 Mn
Sep 30, 2022 -29.58 Mn
Jun 30, 2022 -13.35 Mn
Mar 31, 2022 -5.45 Mn
Dec 31, 2021 -24.60 Mn
Sep 30, 2021 -605,000.00